Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

BACKGROUND: Monoclonal antibodies (mAb), such as trastuzumab are a valuable addition to breast cancer therapy. Data obtained from neoadjuvant settings revealed that antibody-dependent cell-mediated cytotoxicity (ADCC) is a major mechanism of action for the mAb trastuzumab. Conflicting results still...

Descripción completa

Detalles Bibliográficos
Autores principales: Petricevic, Branka, Laengle, Johannes, Singer, Josef, Sachet, Monika, Fazekas, Judit, Steger, Guenther, Bartsch, Rupert, Jensen-Jarolim, Erika, Bergmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029549/
https://www.ncbi.nlm.nih.gov/pubmed/24330813
http://dx.doi.org/10.1186/1479-5876-11-307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029549/
https://www.ncbi.nlm.nih.gov/pubmed/24330813
http://dx.doi.org/10.1186/1479-5876-11-307

Ejemplares similares